Marijuana Stocks & Publicly Traded Cannabis Companies

Steep Hill Nixes Testing Labs Deal With Pazoo

Steep Hill Labs, a prominent marijuana testing company, has severed all contracts with New Jersey-based Pazoo, which had struck a deal to operate Steep Hill-branded cannabis testing labs in Colorado, Nevada and Oregon. In a press release, Steep Hill said the relationship was ended because Pazoo – a New Jersey-based testing lab and wellness company – […]

Read More

Week in Review: California is official, GW’s epilepsy drug & Illinois resignation

By Omar Sacirbey and John Schroyer California’s recreational marijuana campaign makes the November ballot, GW Pharmaceuticals’ MJ-based epilepsy drug could play a role in DEA rescheduling, and a possible new dawn in Illinois’ medical cannabis program. Here’s a closer look at some notable developments in the marijuana industry over the past week.

Read More

Medical Cannabis Company GW Pharma’s Stock Again Jumps

GW Pharmaceuticals – a publicly traded British medical cannabis company conducting clinical trials to determine how effective its medications are against epilepsy – watched its stock surge once again in response to a successful round of testing. News Monday that a phase 3 trial was helpful at treating patients with Lennox-Gastaut Syndrome, a type of epilepsy, […]

Read More

SEC Files Charges Over Alleged MMJ Investment Scam

Wall Street regulators filed civil fraud charges against a company and four people allegedly caught up in a scheme to bilk investors out of nearly a million dollars through a company purported to be a Massachusetts medical cannabis venture. The Securities and Exchange Commission charged that the head of the operation raised $550,000 from investors between 2011 […]

Read More

Week in Review: OH Lawmakers Okay MMJ, Nasdaq says No to MassRoots & MMJ for Vets

By John Schroyer and Omar Sacirbey Ohio lawmakers pass a medical marijuana bill in a bid to undercut a ballot measure, MassRoots’ Nasdaq listing is nixed again, and Congress moves to give military veterans easier access to medical cannabis. Here’s a closer look at several notable developments in the marijuana industry over the past week.

Read More

Nasdaq shoots down MassRoots for stock listing

Denver-based MassRoots, the popular social network for cannabis enthusiasts, failed again to secure a public listing on the Nasdaq, a setback for marijuana companies hoping to trade on a major U.S. stock market. MassRoots said in a press release the Nasdaq linked its decision to the argument that the company, as a pro-marijuana business, could be […]

Read More

FDA Grants U.K. Firm Incentives to Develop Cannabis-Based Drug

U.S. regulators granted GW Pharmaceuticals’ cannabis-based epilepsy drug “orphan” status, enabling the company to receive tax credits and other incentives so it can test the drug on patients with a rare form of the disorder. The U.S. Food and Drug Administration’s decision gives British-based GW the green light to test its Epidiolex medicine for treating […]

Read More

AmeriCann Invests $6.7M in Massachusetts MJ Facilities

AmeriCann, a Denver medical marijuana company, is investing nearly $7 million in a dispensary and a grow facility in two southern coastal Massachusetts towns, according to the Taunton Gazette. The cultivation technology and real estate company is under contract to purchase a nearly 1 million-square-foot site for a medical marijuana grow and processing facility in the […]

Read More

MassRoots Taking Another Stab at Nasdaq Listing

MassRoots, the popular social network for cannabis enthusiasts, is taking another shot at getting listed on the Nasdaq. The Colorado-based company filed an S-1 registration form on Monday with the Securities and Exchange Commission to raise up to $6.5 million by selling shares and warrants – a key part of the process for getting listed on the Nasdaq. […]

Read More

GW Pharmaceuticals Could Make Major Splash in U.S. Cannabis Industry

By Omar Sacirbey A British company that develops cannabis-based medicine is on the verge of a major breakthrough that could ripple across the U.S. marijuana industry. GW Pharmaceuticals will likely seek FDA approval in the fourth quarter of this year to sell an epilepsy drug derived from marijuana, according to an analyst who follows the company.

Read More